Publication | Closed Access

Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial

Hematological MalignancyThrombosisErythropoiesis-stimulating AgentsBone Marrow FailureMalignant Blood DisorderHematologyPharmacotherapyLower-risk Myelodysplastic SyndromesMedicineCell TransplantationAplastic AnemiaMyeloid Neoplasia